Lung Cancer News

The FDA granted accelerated approval to adagrasib for certain adults with non-small cell lung cancer.

Exposure to household air pollutants, especially solid fuel, appeared linked to lung cancer death among individuals who have never smoked, according to a study published in American Journal of Respiratory and Critical Care Medicine.

The FDA issued a complete response letter to Spectrum Pharmaceuticals indicating it could not approve the company’s new drug application that sought approval of poziotinib as treatment for certain patients with lung cancer.

The addition of eftilagimod alpha to pembrolizumab conferred a 40% overall response rate among patients with non-small cell lung cancer unselected for PD-L1, a cohort analysis of the phase 2 TACTI-002 trial showed.

The arthrobacter luteus/albumin ratio demonstrated a strong dose-response relationship with overall lung cancer risk and may be helpful in identifying individuals who should undergo screening, according to study results published in Chest.

Lung Cancer Awareness Month, observed every November, is intended to educate the public about the potential causes and risk factors of the disease.

Less than 6% of eligible Americans have undergone lung cancer screening, according to American Lung Association’s 2022 State of Lung Cancer report.

The FDA approved tremelimumab in combination with durvalumab and platinum-based chemotherapy for certain patients with metastatic non-small cell lung cancer.

The FDA approved cemiplimab-rwlc in combination with platinum-based chemotherapy for first-line treatment of advanced non-small cell lung cancer.

Significant action is necessary to prioritize early detection of lung cancer through expanded screening for high-risk individuals, according to a consensus statement released today.